Feature | Intra-Aortic Balloon Pumps (IABP) | May 31, 2018

IABP Shows Reduced Mortality in SEMPER FI Study

Use of intra-aortic balloon pumps shows a numerical trend toward reduced mortality in patients with extensive myocardial infarction and persistent ischemia

An example of an intra-aortic balloon pump (IABP) from Maquet. The results of the SEMPER FI trial. #europcr2018 #Europcr

An example of an intra-aortic balloon pump (IABP) from Maquet. 

May 31, 2018 — The results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia Following IABP Implantation (SEMPER FI) pilot study showed a positive trend in data presented at the EuroPCR 2018 Congress

The study evaluated the use of an intra-aortic balloon pump (IABP) in patients with extensive myocardial infarction (MI, or heart attack) complicated by persistent ischemia (inadequate blood flow) following primary percutaneous coronary intervention (PCI) – a phenomenon called no-reflow. This small pilot study showed positive trends with IABP in reduction of the primary endpoint (a composite endpoint of mortality, necessity for mechanical support due to hemodynamic deterioration, such as left ventricular assist device (LVAD), and hospital readmission for congestive heart failure at six months). 

Patients with large acute MI and signs of persistent ischemia after successful stenting have a poor prognosis and are likely to develop heart failure in the future. An estimated 30 percent of patients with ST-elevated MI (STEMI) continue to have persistent ischemia even after the primary culprit artery is opened.[1,2]

"Determining which STEMI patients will benefit from IABP has been difficult because of varying results from retrospective and prospective studies," said SEMPER FI co-principal investigator Lokien X. van Nunen, M.D., of Catharina Hospital in Eindhoven, The Netherlands. "We are encouraged by the results of the SEMPER FI pilot study, which showed a strong signal that IABP may be beneficial in patients with extensive acute MI who continue to experience ischemia even after stenting. We expect that these results will bear out in a trial adequately powered to demonstrate a statistically significant reduction in the composite endpoint if this trend were to continue."

SEMPER FI Study Design and Results

The prospective, randomized, comparative, single-center SEMPER FI pilot study evaluated the use of IABP in patients with extensive MI complicated by persistent ischemia after PCI. The study included 100 patients ages 18 to 75 years with acute STEMI (characterized by summed ST-segment deviation of ≥15 mmHg) and insufficient ST-segment resolution on an ECG 10-30 minutes after PCI in the catheterization laboratory. Study participants were randomized to IABP for 12 to 24 hours or no IABP according to guidelines to alleviate persisting ischemia. All were followed up for six months.

Results of this pilot study of 100 patients who presented with large acute MI showed a trend toward decreased mortality, LVAD use and hospital readmission for heart failure within six months with use of IABP. Among the IABP group, 2 percent (one patient) experienced the primary endpoint versus 8 percent (four patients) in the non-IABP group (p=0.16).

About IABP Therapy

Based on extensive literature supporting the hemodynamic effects and safety and effectiveness of intra-aortic balloon counterpulsation (IABC), the U.S. Food and Drug Administration (FDA) has cleared balloon pumps for use in patients with acute coronary syndrome, patients undergoing cardiac and non-cardiac surgery, and patients experiencing complications of heart failure of both ischemic and non-ischemic etiologies.[3] The FDA clearance for these indications was based on results from a comprehensive literature review of IABC devices, which demonstrated low overall rates of complications despite the fact that patients in whom an IAB was implanted had more severe comorbidities and underlying illnesses than patients without a device. Additionally, the literature shows a trend toward fewer device-related complications over time, as balloon catheter sizes have decreased and procedural techniques have improved in recent years.

Other EuroPCR 2018 lake-breaking trials.

References:

1. Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interven Cardiol. 2010;23:429-436.

2. van Nunen LX, van't Veer M, Schampaert S, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction: old and emerging indications. Neth Heart J. 2013;21:554-560.

3. FDA Executive Summary https://www.federalregister.gov/documents/2013/12/30/2013-31218/cardiovascular-devices-reclassification-of-intra-aortic-balloon-and-control-systems-for-acute.

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init